Oxford BioMedica and Novartis build on supply deal as CAR-T med nears finish line – FiercePharma
FiercePharma |
Oxford BioMedica and Novartis build on supply deal as CAR–T med nears finish line
FiercePharma Novartis, in explaining its new CAR-T cancer drug candidate, says T cells like this are drawn from a patient's blood and reprogrammed in the laboratory so that they are genetically coded to hunt the patient's cancer cells and other B cells expressing a … |
